OncoZenge: CTA for phase III study submitted - Redeye

Redeye leaves a comment following OncoZenge’s announcement of having submitted the Clinical Trial Application for its pivotal phase III trial of BupiZenge. We view this as an important milestone that confirms the company’s transition from preparation to execution and materially advances BupiZenge toward a potential European market approval.

Länk till analysen i sin helhet: https://www.redeye.se/research/1143939/oncozenge-cta-for-phase-iii-study-submitted?utm_source=finwire&utm_medium=RSS